What This Bill Does · Plain English
Summary · Congress.gov
Stem Cell Therapeutic and Research Reauthorization Act of 2025 This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA). The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research. Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.
Action Timeline
2025-09-04
Referred to the House Committee on Energy and Commerce.
2025-09-04
Introduced in House
2025-09-04
Introduced in House
Frequently Asked Questions
Did HR.5160 pass?
HR.5160 is still alive. Current stage: PASSED_ONE. Pass likelihood: pending.
What does HR.5160 do?
Stem Cell Therapeutic and Research Reauthorization Act of 2025 This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA). The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and prov…
Who sponsored HR.5160?
HR.5160 was sponsored by Christopher H. Smith (R-New Jersey).
Full Bill Text
119 HR 5160 IH: Stem Cell Therapeutic and Research Reauthorization Act of 2025 U.S. House of Representatives 2025-09-04 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. I 119th CONGRESS 1st Session H. R. 5160 IN THE HOUSE OF REPRESENTATIVES September 4, 2025 Mr. Smith of New Jersey (for himself, Ms. Matsui , Mr. Bilirakis , Ms. Pingree , Ms. Tenney , and Mr. Mfume ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes. 1. Short title This Act may be cited as the Stem Cell Therapeutic and Research Reauthorization Act of 2025 . 2. Reauthorization of the C.W. Bill Young Cell Transplantation Program Section 379B of the Public Health Service Act ( 42 U.S.C. 274m ) is amended— (1) by striking appropriated $31,009,000 and inserting the following: appropriated— (1) $31,009,000 ; (2) in paragraph (1), as so inserted, by striking the period at the end and inserting ; and ; and (3) by adding at the end the following: (2) $33,009,000 for each of fiscal years 2027 through 2031. . 3. Cord blood inventory Section 2(g) of the Stem Cell Therapeutic and Research Act of 2005 ( 42 U.S.C. 274k note) is amended by striking 2026 and inserting 2031 .
Loading intelligence layer…